| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 4.1 | 0.1 |
| Net income | -78.1 | -56.9 |
| EPS (diluted, $ a share) | $-1.08 | $-1.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +4505.6% |
|---|
10-Q filed with the SEC, NASDAQ: FDMT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
4D Molecular Therapeutics, Inc.: key numbers
- Share price
- $11.29Close, Nov 16
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from 4D Molecular Therapeutics, Inc.
All →4D Molecular Therapeutics Financial Results
4D Molecular Therapeutics reported Q3 2026 financial results and provided updates on its 4D-150 clinical programs, including the completion of randomization for the 4FRONT-2 Phase 3 trial in wet AMD. The company ended the quarter with $375 million in cash, which is expected to fund operations into the second half of 2028.
“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD.”
David Kirn, MD, Co-founder, President and Chief Executive Officer
4D Molecular Therapeutics CLO Scott Bizily Sells $21K of Stock
Scott Bizily, CLO, sold 1,635 shares of 4D Molecular Therapeutics, Inc. at $12.84 a share, worth $21K in total on Oct 16, 2026. Shares held after the trade: 8,617 (-15.9%).
- Value
- $21K
- Shares
- 1,635
- Price
- $12.84
- Role
- CLO
- Holding change
- -15.9%
- Trade date
- Oct 16, 2026
4D Molecular Therapeutics Insider David Kirn Sells $750K of Stock
David Kirn sold 58,061 shares of 4D Molecular Therapeutics, Inc. at $12.92 a share, worth $750K in total on Oct 5, 2026. Shares held after the trade: 709,425 (-7.6%).
- Value
- $750K
- Shares
- 58,061
- Price
- $12.92
- Holding change
- -7.6%
- Trade date
- Oct 5, 2026
4D Molecular Therapeutics Clinical Trial Data
4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.
4D Molecular Therapeutics Insider David Kirn Sells $811K of Stock
David Kirn sold 58,333 shares of 4D Molecular Therapeutics, Inc. at $13.90 a share, worth $811K in total on Sep 14, 2026. Shares held after the trade: 767,486 (-7.1%).
- Value
- $811K
- Shares
- 58,333
- Price
- $13.90
- Holding change
- -7.1%
- Trade date
- Sep 14, 2026